Overview

Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

Status:
Completed

Trial end date:
2008-10-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 6-week acute treatment in study NCT00839423 / 11492A.

Phase:

Phase 2

Details

Lead Sponsor:

H. Lundbeck A/S

Treatments:

Vortioxetine